Hartford Investment Management Co. Sells 1,294 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Hartford Investment Management Co. cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 77,027 shares of the biopharmaceutical company’s stock after selling 1,294 shares during the quarter. Hartford Investment Management Co.’s holdings in Gilead Sciences were worth $7,115,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in GILD. HHM Wealth Advisors LLC lifted its holdings in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares in the last quarter. nVerses Capital LLC purchased a new position in Gilead Sciences during the third quarter worth $25,000. YANKCOM Partnership bought a new position in Gilead Sciences during the 4th quarter valued at about $28,000. Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $29,000. Finally, Valued Wealth Advisors LLC grew its position in Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GILD has been the topic of a number of research reports. Wells Fargo & Company raised their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Truist Financial lifted their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Bank of America reissued a “buy” rating and set a $109.00 price target on shares of Gilead Sciences in a research report on Tuesday, December 10th. Finally, Citigroup started coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 price objective for the company. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $98.39.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares in the company, valued at $815,198.80. The trade was a 43.21 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 572,824 shares of company stock valued at $53,611,715. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Trading Up 0.7 %

Shares of Gilead Sciences stock opened at $96.14 on Wednesday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $100.51. The firm’s 50-day moving average price is $93.07 and its 200 day moving average price is $86.99. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $119.82 billion, a PE ratio of 1,068.22, a P/E/G ratio of 1.25 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. On average, sell-side analysts predict that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.